Stay updated on Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial

Sign up to get notified when there's something new on the Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:15:25.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the cumulative dose of otelixizumab being investigated in a Phase I/IIa study for new-onset autoimmune Type 1 Diabetes Mellitus patients. This change reflects an exploration of the tolerability dose response to determine the therapeutic index of otelixizumab in halting/slowing Beta-cell destruction.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:03.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes a detailed explanation of eligibility criteria and examples such as a person's general health condition or prior treatments.
    Difference
    54%
    Check dated 2024-05-22T20:32:43.000Z thumbnail image

Stay in the know with updates to Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Otelixizumab in New-Onset Type 1 Diabetes Clinical Trial page.